Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multimorbidity Clusters Among People Aged 65 Years and Over in Australia: A Nationwide Cross-Sectional Data Linkage Study.

The Medical journal of Australia·2026
Same author

Preliminary development of a Risk Factor Index to identify older adults at risk of adverse medication-related outcomes: A Delphi Study.

Exploratory research in clinical and social pharmacy·2026
Same author

Monitoring the safety of the adjuvanted human papillomavirus vaccine HPV-16/18-AS04 in association with pregnancy and potential immune-related diseases in China: A retrospective observational cohort study.

Human vaccines & immunotherapeutics·2026
Same author

Platinum nanoparticles-loaded cherry radish polysaccharides with high oxidase-like activity for rapid colorimetric analysis of ascorbic acid.

International journal of biological macromolecules·2026
Same author

Brain pathology in relation to somatic diseases: Exploring the body-brain crosstalk.

Journal of internal medicine·2026
Same author

The prevalence, determinants, and mechanisms of traditional Chinese medicine service utilization among healthcare professionals: a study based on the Andersen Behavioral Model.

Frontiers in public health·2026

Related Experiment Videos

Long-Term Cardiovascular Risks of Anticholinergic Versus Non-Anticholinergic Antidepressants: A Target Trial

Yang Xu1,2, Hong Xu3, Jinxin Guo4

  • 1Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.

Pharmacoepidemiology and Drug Safety
|July 15, 2026
PubMed
Summary

Anticholinergic antidepressants are linked to a higher risk of cardiovascular events, including stroke and heart attack. Prioritizing antidepressants with lower anticholinergic burden is recommended for patient safety.

Keywords:
anticholinergicsantidepressantcardiovascular eventnegative control

Related Experiment Videos

Area of Science:

  • Pharmacovigilance
  • Cardiovascular Epidemiology
  • Clinical Pharmacology

Background:

  • Antidepressants are frequently prescribed globally.
  • The cardiovascular risks associated with anticholinergic properties of antidepressants are not well understood.

Purpose of the Study:

  • To investigate the association between anticholinergic antidepressant use and cardiovascular events.
  • To compare cardiovascular risk between anticholinergic and non-anticholinergic antidepressant users.

Main Methods:

  • An active-comparator new-user design study was conducted using UK Biobank data (2006-2021).
  • Propensity score matching (PSM), proximal causal inference (PCI), and negative control outcome calibration (NCOC) were used to adjust for confounding.
  • The primary outcome was hospitalization or death from cardiovascular events.

Main Results:

  • The study included 24,547 anticholinergic and 20,519 non-anticholinergic antidepressant users.
  • Anticholinergic antidepressant use was associated with an increased risk of cardiovascular events (HD_PSM+PCI: 59.96; HD_PSM+NCOC: 31.35 per 10,000 person-years).
  • Elevated risks were observed for ischemic stroke, acute coronary syndrome, heart failure, arrhythmias, arterial disease, and venous thromboembolism.

Conclusions:

  • Anticholinergic antidepressants may elevate the risk of cardiovascular events compared to non-anticholinergic alternatives.
  • Clinical practice should prioritize antidepressant therapies with a reduced anticholinergic burden.